drugset / Trial / NCT05253066

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

NCT05253066

Phase 2/3 Unknown 130 enrolled Shengjing Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open, multicenter, randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane (+/- goserelin) versus chemotherapy in the neoadjuvant treatment of stage II-III HR +/HER2- breast cancer patients with poor response to previous chemotherapy.

Timeline

Start
2022-02-25
Primary completion
2022-07-31
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Docetaxel Small molecule
Comparator Epirubicin Small molecule
Subject Exemestane Small molecule
Subject Goserelin Other / unclassified
Subject Tucidinostat Small molecule

Indications